French-American Partnership to Develop Anti-hypertension Drugs

A partnership has been formed between an American drug developer and two major French research institutes to promote the development of drugs to treat hypertension and related cardiovascular diseases.

QGC001, an experimental drug designed to facilitate control of blood pressure in patients who are resistant to currently available anti-hypertension drugs, will be the first drug investigated under the new agreement. Quantum Genomics Corp. (Jersey City, NJ, USA) will carry out pre-clinical and clinical development while the French national institute for health, Inserm, and CNRS, France's national center for scientific research, will seek to understand the compound's physiopathology, chemistry, and mechanism of action. Quantum Genomics maintains the right to exploit three patents and associated knowledge related to the drug.

"We are delighted to be partnering with Inserm and CNRS, two of the world's leading healthcare research organizations,” said Lionel Ségard, CEO of Quantum Genomics Corp. "This project lets Quantum Genomics demonstrate its ability to develop new drugs in compliance with international regulatory guidelines. It also significantly reinforces Quantum Genomics' potential in R&D in the field of cardiovascular diseases.”


Related Links:
Quantum Genomics Corp
Inserm
CNRS